| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1378/CHEST.10-1194 |
| P953 | full work available at URL | http://intl.chestjournal.org/cgi/content/abstract/139/1/28 |
| https://api.elsevier.com/content/article/PII:S0012369211600111?httpAccept=text/xml | ||
| https://api.elsevier.com/content/article/PII:S0012369211600111?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 20688929 |
| P5875 | ResearchGate publication ID | 45508328 |
| P50 | author | Jose A Castro-Rodriguez | Q64437861 |
| P2093 | author name string | Hugo Neffen | |
| Gustavo J. Rodrigo | |||
| P2860 | cites work | Anti-IgE for chronic asthma in adults and children | Q24246484 |
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q28131636 | ||
| Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007 | Q29615702 | ||
| Interaction revisited: the difference between two estimates | Q29619619 | ||
| Safety and tolerability of omalizumab | Q33383804 | ||
| Anti-IgE therapy in asthma: rationale and therapeutic potential | Q34102480 | ||
| Severe asthma: lessons from the Severe Asthma Research Program | Q36701751 | ||
| Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma | Q36971436 | ||
| Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). | Q43694602 | ||
| Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma | Q43701894 | ||
| The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics | Q43723871 | ||
| Features that distinguish those who die from asthma from community controls with asthma | Q44370406 | ||
| Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma | Q44841358 | ||
| Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. | Q47387899 | ||
| Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma | Q48382331 | ||
| Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. | Q50883385 | ||
| Determining a minimal important change in a disease-specific Quality of Life Questionnaire. | Q51136958 | ||
| Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. | Q53310678 | ||
| Inhibition of allergic reactions with antibodies to IgE | Q71883063 | ||
| What are minimal important changes for asthma measures in a clinical trial? | Q72998939 | ||
| Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma | Q84893829 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| placebo | Q269829 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 28-35 | |
| P577 | publication date | 2010-08-05 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review | |
| Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma | |||
| P478 | volume | 139 |
| Q38661772 | 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. |
| Q36787683 | A mobile instrumentation platform to distinguish airway disorders. |
| Q37360030 | A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma |
| Q34841589 | A soluble form of the high affinity IgE receptor, Fc-epsilon-RI, circulates in human serum |
| Q47937170 | ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine |
| Q89821328 | Adherence to omalizumab: A multicenter "real-world" study |
| Q33934140 | Aligning mouse models of asthma to human endotypes of disease |
| Q37994807 | B cells in allergic diseases: bad or better? |
| Q38240474 | Biological Modulators in Eosinophilic Diseases. |
| Q50046297 | Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. |
| Q42372168 | Bronchial asthma--Issues for the developing world |
| Q48484600 | Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. |
| Q39527744 | Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation |
| Q35890173 | Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. |
| Q49174402 | Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. |
| Q37976485 | Current treatment of severe asthma |
| Q38597715 | Drug therapies in severe asthma - the era of stratified medicine. |
| Q58299909 | Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media |
| Q35889211 | Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study |
| Q26861260 | Emerging therapies for severe asthma |
| Q57638900 | FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children |
| Q38584348 | From IgE to clinical trials of allergic rhinitis. |
| Q33813077 | Ganoderma formosanum polysaccharides attenuate Th2 inflammation and airway hyperresponsiveness in a murine model of allergic asthma |
| Q36573253 | Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation |
| Q28392274 | Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations |
| Q38016152 | HSP: Bystander Antigen in Atopic Diseases? |
| Q34142714 | Have we overestimated the benefit of human(ized) antibodies? |
| Q26795564 | Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review |
| Q41633977 | Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? |
| Q30393965 | International consensus on (ICON) pediatric asthma |
| Q35078215 | Long-term benefits of omalizumab in a patient with severe non-allergic asthma |
| Q35040868 | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis |
| Q38733745 | Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy. |
| Q34336901 | Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study |
| Q38083320 | Microbes and mucosal immune responses in asthma. |
| Q52810841 | Modifying the trajectory of asthma-are there lessons from the use of biologics in rheumatology? |
| Q38113498 | Newer treatments in the management of pediatric asthma |
| Q64083024 | Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
| Q38310407 | Omalizumab for the treatment of chronic urticaria |
| Q37634329 | Omalizumab in an allergology clinic: real life experience and future developments |
| Q34604574 | Omalizumab in children |
| Q60909264 | Omalizumab in children with severe allergic disease: a case series |
| Q64284997 | Omalizumab induced Takotsubo syndrome: case report |
| Q34303895 | Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. |
| Q58583982 | Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness |
| Q38118172 | Omalizumab: a review of its use in patients with severe persistent allergic asthma |
| Q36055963 | Omalizumab: clinical use for the management of asthma. |
| Q39936622 | Outpatient management of asthma in children |
| Q37981091 | Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy. |
| Q28073074 | Personalized Medicine in Allergy |
| Q38062584 | Phenotyping airways disease: an A to E approach. |
| Q38256105 | Principal findings of systematic reviews for chronic treatment in childhood asthma. |
| Q38789811 | Real-life Efficacy of Omalizumab After 9 Years of Follow-up. |
| Q37171325 | Refractory asthma - An old disorder: Novel approaches for effective control |
| Q37852717 | Safety of omalizumab in asthma |
| Q34858558 | Severe Asthma: The Evolution of Patient-directed Management |
| Q28071832 | Severe asthma: anti-IgE or anti-IL-5? |
| Q59792091 | Severe refractory asthma: current treatment options and ongoing research |
| Q23916999 | Stepping down asthma treatment: how and when |
| Q38474060 | Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents |
| Q27016035 | Tailored therapy for severe asthma |
| Q38673097 | Targeted therapy in severe asthma today: focus on immunoglobulin E. |
| Q30360362 | Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. |
| Q38087697 | The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations |
| Q38483005 | The discovery and development of omalizumab for the treatment of asthma |
| Q34480446 | The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial |
| Q37979254 | The management of asthma and chronic obstructive pulmonary disease: current status and future perspectives |
| Q38843261 | The path to personalized medicine in asthma. |
| Q38063791 | The potential of biologics for the treatment of asthma |
| Q37531868 | The role and choice criteria of antihistamines in allergy management - expert opinion. |
| Q38007833 | Therapies for allergic inflammation: refining strategies to induce tolerance |
| Q84071305 | Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs |
| Q35117827 | Update on optimal use of omalizumab in management of asthma. |
| Q52658055 | Use of Placebo in Supplementation Studies-Vitamin D Research Illustrates an Ethical Quandary. |
| Q84582191 | [Pulmonary allergic reactions] |
Search more.